Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Lipotrue, S.l.

Antalgenics, S.l.

Isabel Devesa Giner

Antonio Vicente Ferrer Montiel

Giorgina Mangano

Francesca Mancini

Gregorio Fernández Ballester

Cristina Bartella

Ariadna Grau-Campistany

Silvia Pastor

Gregorio Joaquin Fernandez Ballester

Patricia Carulla

Juan Carlos Escudero

Tracey Pirali

Armando Genazzani

Asia Fernandez Carvajal

Julia A Boras

Pastor Silvia

The invention relates to peptides capable of inhibiting neuronal exocytosis and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions, disorders and/or diseases mediated by neuronal exocytosis, such as wrinkles, excessive perspiration, pruritus, cutaneous inflammation, dermatitis, atopia, psoriasis, vascular hyperreactivity, rosacea, acne, hair growth, wound healing, calluses, warts, or sensitive skin conditions, such as ulcers and lesions on the skin.

Peptides for inhibiting cholinergic calcitonin gene-related peptide (CGRP) and acetylcholine (ACH) release or inhibiting sensitization-mediated by TRPV1-mediated excitability in sensory neurons and methods of use thereof

Peptides able to inhibit the muscarinic receptor M3 activity and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions mediated by the muscarinic receptor M3 activity, such as excessive perspiration, inflammation, sebum production, and cell adhesion, motility, growth, differentiation and proliferation.

Peptides having inhibitory activity on muscarinic receptor M3

The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs.

Peptides and compositions for use in cosmetics and medicine

The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R, R, Rand Rare independently selected from H, (C-C)alkyl, unsaturated (C-C)hydrocarbon, and (C-C)cycloalkyl, being these groups optionally substituted; Ris hydrogen or halogen; Ris selected from H, (C-C)alkyl, unsaturated (C-C)hydrocarbon, (C-C)cycloalkyl, (C-C)aryl, and (C-C)heteroaryl, being these groups optionally substituted; and Ris selected from (C-C)alkyl, unsaturated (C-C)hydrocarbon, (C-C)aryl, and (C-C)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications. 

TRPV1 modulator compounds

Growing community of inventors

Elche, Spain

Isabel Devesa Giner